Member Info for Laura2022

With those large trades

Going well

PYC and VAL have a JV on that and lots of positive contracts coming the last few weeks , not material but all helps

Inaphaea is delighted to confirm the execution of a further contract for the provision of cell-based assays to UK biotech company, Amply Discovery Limited ("Amply"). The multiphase contract, potentially worth over £100,000 over a 8 month period, will evaluate various formulations of Amply's developmental siRNA targets in Inaphaea's Triple Negative Breast Cancer (TNBC) Patient Derived Cells (PDCs) as stand-alone agents and in combination with standard of care drugs. The deal includes an upfront payment to Inaphaea of approximately £31,000 with an additional approximately £21,000 payment on completion of the first phase after 4 months and £10,500 on completion of the remaining in-vitro phase after a further 6 weeks. Successful candidates have the option to be evaluated in-vivo using selected PDCs through one of Inaphaea's partners.

Also RRR took him on Feb 2024 as a "consultant " and PPP "fired him".in Nov 2024

...but the wording said "resigned '

German Chancellor Olaf Sholz has defended his decision to call Russian President Vladimir Putin on Friday, telling reporters " it was and still is the right thing to do".

Speaking to reporters at the G20 summit in Brazil, Scholz says he called Putin "because this must be made clear to him: He has a responsibility. He must end the war..."

Discussions at leadership level must take place for this to happen, he adds.

He also says he has "explained very clearly" why he thinks its right to not send Taurus missiles to Ukraine, adding that the missiles could only be used if "responsibility for targeting" was shared, and it is not something he can "take responsibility for".

He says: "We have a clear understanding that the powerful weapons we have supplied so far, the long-range artillery, the rocket launchers, cannot be used to penetrate deep into the Russian hinterland."

🚀 Congratulations to our client Numab Therapeutics AG on the initiation of their Phase 1 clinical study of NM32!

We’re thrilled to see NM32, a tri-specific T-cell engager targeting ROR1 for patients with solid tumours, advance to this important milestone. At Physiomics plc, we were proud to support this project by developing a mathematical model establishing the preclinical PKPD relationships using both in vitro and in vivo data, that could be used to support the dose justification for this innovative therapy's Phase 1 trial.

See the poster for this work with Numab here: https://lnkd.in/eHEM_Wfc

Congratulations again to the Numab team! We look forward to seeing the impact of NM32 on patients who need it most.

Best wishes whatever you decide

Atb

You'll have more credibility if you simply say if you bought and hold

How hard can that be?

18-Nov-24 16:43:37 53.2682 1,100,000 Buy* 585.95k

18-Nov-24 16:35:29 52.75 1,001,512 Buy* 528.30k

1mln buy late Friday

Another 1mln today

I've posted lots of time on over 15 shares msuk

It's simple really, are you invested and for how long ?

Clarets

If people posted more...like yourself. You said you were impressed by the presentation and watched it but never once posted anything?

Tricky

No wonder someone wanted 2.5% PYC 2 Fridays ago

1) very low salaries...eg £70k CEO v £300K Ceo like WSG

2) low overheads

3)growing revenues

4) growing pipeline

5) cashed up

6] growth markets of drug discovery and biostatistics

7]potential for large uplifts..eg if VAL201 comes in or personalised dosing app takes off in America

7) very low shares in issue (only 230mln)

10:36

30 October 2024 Posted in News by Press Office

Following the first Labour budget for 14 years, the Association of the British Pharmaceutical Industry (ABPI) welcomes Chancellor Rachel Reeves’ measures to improve UK life sciences competitiveness.

With a focus on stability, investment, and long-term growth, key announcements in the Budget included increases in NHS funding, a £520m life sciences innovative manufacturing fund, and investment in research and development, including increased funding for the National Institute for Health Research (NIHR).

November 8th posts sorry ..Friday 8th

See the posts from Tofffe and myself Nov 1st Friday

1) fund buying like Vulpesinvest.com

2) Large VCT buyer

3) private buyer

2.5% of PYC bought

£42k 2 Fridays ago

Largest trade for 12mths+

Now dangerous to be short/on side lines

1) charts bottom

2) potential for contracts /$125mln assset sale

3) company update

4) shorts closing

5(dark pool buying (see HelloDave posts)

Yes, and there is a plethora of positive news at PYC and for oncology more widely with UK investment into the sector

Great see AGL now above 12p

Wonder if that parasite GordonGheko still posts , I filtered them 4 months ago

For me AGL PYC SCLP are the best oncology stocks

Toffee

The person who put the chart up probably bought in a few lots Friday then sold today

He's (msuk) done this several times over last 2yrs)

Day trading nonsense

As you say, 100% rise still only values PYC at £2.7mln market

Agm should give some future direction tommorow